SHR-A1811: Clinical Trials

37 trials of SHR-A1811, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 not yet recruiting, 14 recruiting, 5 unknown, 2 active not recruiting. 37 Phase 2, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 237Not yet recruiting 16, Recruiting 14, Unknown 5, Active not recruiting 2
Phase 17Recruiting 3, Not yet recruiting 2, Unknown 2

Follow SHR-A1811: new trials by email Literature Review of SHR-A1811 trials Research Report on SHR-A1811

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC)
Phase 2Not yet recruitingFudan University3582026-10-012026-10-02
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
SHR-A1811, THPy - HER2-positive Breast Cancer
Phase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang University802026-09-012026-08-26
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients
SHR-A1811 - HER2positive, Advanced Breast Cancer
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital602026-06-102026-06-11
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Rezetecan for Injection (SHR-A1811), Trastuzumab Deruxtecan for Injection (T-DXd) - Advanced Breast Cancer
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University1002026-06-012026-06-05
Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer
Dalpiciclib 125mg, Aromatase Inhibitor, SHR-A1811 - Breast Cancer, HR Positive/HER2 Low Breast Cancer
Phase 2Not yet recruitingTang-Du Hospital202026-06-012026-06-11
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
SHR-A1811, Pertuzumab, trastuzumab - Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital1002026-05-012026-04-14
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute1002026-03-312026-02-18
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Serplulimab, SHR-A1811 - Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Phase 2Not yet recruitingXijing Hospital842026-03-252026-03-12
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
SHR-A1811, SKB264, Pembrolizumab - HER2-negative Breast Cancer
Phase 2Not yet recruitingFudan University302026-03-152026-03-12
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
SHR-A1811, Adebrelimab (PD-L1 inhibitor), Taxane Chemotherapy - Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2492026-02-152026-01-05
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Nab paclitaxel, Carboplatin, Trastuzumab - HER2-positive Early Breast Cancer
Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2002025-12-252026-01-21
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies
SHR-A1811, Trastuzumab Rezetecan - Urachal Cancer, Advanced Solid Tumor Cancer
Phase 2RecruitingSheng Zhang902025-12-182025-12-30
Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer
SHR-A1811, Letrozole, TAC/AC-T - Breast Cancer
Phase 2Not yet recruitingFirst Hospital of China Medical University1202025-12-012025-12-26
SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
SHR-A1811 - Early Breast Cancer, HER2 + Breast Cancer
Phase 2Not yet recruitingChuan Wang302025-10-012025-08-26
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases
SHR-A1811, radiotherapy - Breast Cancer, Brain Metastases
Phase 1 / Phase 2Not yet recruitingPeking University Cancer Hospital & Institute512025-09-302025-09-17
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2882025-09-102025-09-18
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
SHR-A1811, Carboplatin, Oxaliplatin - Ovarian Cancer
Phase 1 / Phase 2Not yet recruitingTongji Hospital902025-06-012025-05-25
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Trastuzumab, Adebrelimab, Apatinib - Gastric Cancer, HER2 + Gastric Cancer
Phase 2Not yet recruitingChina Medical University, China1402025-05-012025-03-18
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
SHR-A1811, Adebelimab injection, Bevacizumab injection - Recurrent or Metastatic Cervical Cancer
Phase 1 / Phase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1002025-04-252025-06-06
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
SHR-A1811, Pertuzumab, Albumin-Paclitaxel - Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Phase 2RecruitingHenan Cancer Hospital1802025-04-162025-06-23

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Breast Neoplasms (15)  ·  Triple Negative Breast Neoplasms (4)  ·  Ovarian Neoplasms (2)  ·  Pathologic Complete Response (2)  ·  Biliary Tract Neoplasms (1)  ·  Brain Neoplasms (1)  ·  Meningeal Carcinomatosis (1)  ·  Neoplasm, Residual (1)  ·  Paget Disease, Extramammary (1)  ·  Recurrence (1)  ·  Stomach Neoplasms (1)  ·  Urachal cancer (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Fudan University (10)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (5)  ·  Henan Cancer Hospital (2)  ·  Jiangsu HengRui Medicine Co., Ltd. (2)  ·  Peking University Cancer Hospital & Institute (2)  ·  Beijing GoBroad Hospital (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  China Medical University, China (1)  ·  Chuan Wang (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  First Hospital of China Medical University (1)  ·  Hebei Medical University Fourth Hospital (1)  ·  Huihua Xiong (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Sheng Zhang (1)

Countries

China (30)

Top investigators

Zhimin Shao, Professor (2)  ·  Bin Shao (1)  ·  Biyun Wang, Chief physician (1)  ·  Caigang Liu, MD (1)  ·  Dongmei Ji, Doctor (1)  ·  Hanfang Jiang (1)  ·  Hongxia Wang, Chief physician (1)  ·  Qinglei Gao (1)  ·  Wei Zhao (1)  ·  Xiaoyan Li (1)  ·  Zhenzhen Liu (1)  ·  Zhimin Shao, M.D. (1)

Results publications

PMID 38362377, PMID 39004647, PMID 40020696, PMID 40563015, PMID 42129335, PMID 42579830